Mirum Pharmaceuticals

At Mirum Pharmaceuticals, we are dedicated to developing "remarkable" medicines that address the unmet needs of patients with rare liver diseases. Our name, derived from the Latin word "mirum," signifies our commitment to creating extraordinary solutions for those affected by rare conditions. Driven by the conviction that patients deserve transformative care, our vision extends beyond mere treatments; we strive to cultivate moments of joy and hope for families navigating the difficulties of rare diseases. Our focus on innovation fosters the development of therapies that are not only scientifically advanced but also intimately connected to patient experiences.

Our research and development strategy is founded on solid scientific evidence and a passionate commitment to our community. We prioritize meaningful collaborations with patients and families to identify what matters most, enhancing the relevance of our clinical trials and therapeutic discoveries. Mirum’s leading investigational product, LIVMARLI (maralixibat), represents a significant step forward in the management of cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis. By pioneering treatments that address the underlying causes of rare diseases, we are committed to changing the trajectory of care and improving lives. Join us on our journey to make rare diseases less isolating and more manageable, as we empower patients and turn transformative scientific breakthroughs into everyday realities.